The value of staging and serial follow-up investigations in patients with completely resected, primary, cutaneous malignant melanoma

1985 ◽  
Vol 72 (8) ◽  
pp. 614-617 ◽  
Author(s):  
Patricia A. Kersey ◽  
N. A. Iscoe ◽  
J. A. P. Gapski ◽  
D. Osoba ◽  
L. From ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Cutaneous Malignant Melanoma ◽  
Primary Cutaneous Malignant Melanoma

scholarly journals Late Metastases from a Thin Primary Cutaneous Malignant Melanoma

2020 ◽  
Vol 78 (1) ◽  
pp. 71-74
Author(s):  
Regina Caldas ◽  
Filipa T. Almeida ◽  
Teresa Pereira ◽  
Inês Carvalho ◽  
Sofia D. Carvalho ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Good Prognosis ◽  
Cutaneous Malignant Melanoma ◽  
Common Type ◽  
Tumor Thickness ◽  
Primary Cutaneous Malignant Melanoma ◽  
Great Ability ◽  
The Third ◽  
History Of

Cutaneous malignant melanoma is the third most common type of skin cancer, and its incidence has been rising. Its mortality rate is considerable, due to an aggressive phenotype and great ability of dissemination, mainly in the first years of follow- -up. Late recurrences, those presenting more than 10 years after diagnosis, are rare. The main prognostic factor of cutaneous malignant melanoma is tumor thickness, which also guides management. Thin tumors often have a good prognosis. We report a case of a 66-year-old woman with a history of excision of a thin primary cutaneous malignant melanoma of the dorsum, presenting 16 years later with an unexpected, rapidly progressing and lethal recurrence.

Surgery for Primary Cutaneous Malignant Melanoma

1985 ◽  
Vol 3 (2) ◽  
pp. 315-326 ◽  
Author(s):  
Daniel F. Roses ◽  
Matthew N. Harris ◽  
Stephen L. Gumport
Keyword(s):  
Malignant Melanoma ◽  
Cutaneous Malignant Melanoma ◽  
Primary Cutaneous Malignant Melanoma

scholarly journals TRIM study protocol - a prospective randomized multicenter Trial to assess the Role of Imaging during follow-up after radical surgery of stage IIB-C and III cutaneous malignant Melanoma

BMC Cancer ◽  
2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Ylva Naeser ◽  
Hildur Helgadottir ◽  
Yvonne Brandberg ◽  
Johan Hansson ◽  
Roger Olofsson Bagge ◽  
...  
Keyword(s):  
Quality Of Life ◽  
High Risk ◽  
Malignant Melanoma ◽  
Potential Benefit ◽  
Radical Surgery ◽  
Multicenter Trial ◽  
Cutaneous Malignant Melanoma ◽  
Link Type

Abstract Background The incidence of cutaneous malignant melanoma (CMM) is increasing worldwide. In Sweden, over 4600 cases were diagnosed in 2018. The prognosis after radical surgery varies considerably with tumor stage. In recent years, new treatment options have become available for metastatic CMM. Early onset of treatment seems to improve outcome, which suggests that early detection of recurrent disease should be beneficial. Consequently, in several countries imaging is a part of the routine follow-up program after surgery of high risk CMM. However, imaging has drawbacks, including resources required (costs, personnel, equipment) and the radiation exposure. Furthermore, many patients experience anxiety in waiting for the imaging results and investigations of irrelevant findings is another factor that also could cause worry and lead to decreased quality of life. Hence, the impact of imaging in this setting is important to address and no randomized study has previously been conducted. The Swedish national guidelines stipulate follow-up for 3 years by clinical examinations only. Methods The TRIM study is a prospective randomized multicenter trial evaluating the potential benefit of imaging and blood tests during follow-up after radical surgery for high-risk CMM, compared to clinical examinations only. Primary endpoint is overall survival (OS) at 5 years. Secondary endpoints are survival from diagnosis of relapse and health-related quality of life (HRQoL). Eligible for inclusion are patients radically operated for CMM stage IIB-C or III with sufficient renal function for iv contrast-enhanced CT and who are expected to be fit for treatment in case of recurrence. The planned number of patients is > 1300. Patients are randomized to clinical examinations for 3 years +/− whole-body imaging with CT or FDG-PET/CT and laboratory tests including S100B protein and LDH. This academic study is supported by the Swedish Melanoma Study Group. Discussion This is the first randomized prospective trial on the potential benefit of imaging as a part of the follow-up scheme after radical surgery for high-risk CMM. Results The first patient was recruited in June 2017 and as of April 2020, almost 500 patients had been included at 19 centers in Sweden. Trial registration ClinicalTrials.gov, NCT 03116412. Registered 17 April 2017, https://clinicaltrials.gov/ct2/show/study/NCT03116412

Sign in / Sign up

Export Citation Format

Share Document